Drug Insight

The use of bisphosphonates for the prevention and treatment of osteoporosis in men

Sue A. Brown, Theresa Guise

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Osteoporosis has long been recognized as a disease affecting postmenopausal women but it has become increasingly clear that men are affected by low bone density and suffer the consequences of osteoporotic fractures. Men attending clinical urological practices might be at raised risk of bone loss due to hypogonadism, either identified during work-up of erectile dysfunction or induced by androgen deprivation therapy for treatment of prostate cancer. The availability of bisphosphonate drugs with proven efficacy in fracture reduction has revolutionized osteoporosis therapy in the past decade. The use of these agents has been traditionally based on data obtained predominantly from postmenopausal women and cases of glucocorticoid-induced osteoporosis, but data are becoming increasingly available to justify their use in men. Despite the availability and favorable safety profile of bisphosphonates, many patients are not receiving therapy. This article serves to review the data regarding bisphosphonate use in men, discussing particularly the pharmacology and mechanisms of action of these agents, and findings from clinical studies supporting their use for fracture prevention.

Original languageEnglish (US)
Pages (from-to)310-320
Number of pages11
JournalNature Clinical Practice Urology
Volume4
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Diphosphonates
Osteoporosis
Pharmaceutical Preparations
Fracture Fixation
Osteoporotic Fractures
Hypogonadism
Erectile Dysfunction
Therapeutics
Bone Density
Glucocorticoids
Androgens
Prostatic Neoplasms
Pharmacology
Safety
Bone and Bones

ASJC Scopus subject areas

  • Urology
  • Nephrology

Cite this

Drug Insight : The use of bisphosphonates for the prevention and treatment of osteoporosis in men. / Brown, Sue A.; Guise, Theresa.

In: Nature Clinical Practice Urology, Vol. 4, No. 6, 06.2007, p. 310-320.

Research output: Contribution to journalArticle

@article{43d606db686e416e92ff3eadb32215fd,
title = "Drug Insight: The use of bisphosphonates for the prevention and treatment of osteoporosis in men",
abstract = "Osteoporosis has long been recognized as a disease affecting postmenopausal women but it has become increasingly clear that men are affected by low bone density and suffer the consequences of osteoporotic fractures. Men attending clinical urological practices might be at raised risk of bone loss due to hypogonadism, either identified during work-up of erectile dysfunction or induced by androgen deprivation therapy for treatment of prostate cancer. The availability of bisphosphonate drugs with proven efficacy in fracture reduction has revolutionized osteoporosis therapy in the past decade. The use of these agents has been traditionally based on data obtained predominantly from postmenopausal women and cases of glucocorticoid-induced osteoporosis, but data are becoming increasingly available to justify their use in men. Despite the availability and favorable safety profile of bisphosphonates, many patients are not receiving therapy. This article serves to review the data regarding bisphosphonate use in men, discussing particularly the pharmacology and mechanisms of action of these agents, and findings from clinical studies supporting their use for fracture prevention.",
author = "Brown, {Sue A.} and Theresa Guise",
year = "2007",
month = "6",
doi = "10.1038/ncpuro0816",
language = "English (US)",
volume = "4",
pages = "310--320",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Drug Insight

T2 - The use of bisphosphonates for the prevention and treatment of osteoporosis in men

AU - Brown, Sue A.

AU - Guise, Theresa

PY - 2007/6

Y1 - 2007/6

N2 - Osteoporosis has long been recognized as a disease affecting postmenopausal women but it has become increasingly clear that men are affected by low bone density and suffer the consequences of osteoporotic fractures. Men attending clinical urological practices might be at raised risk of bone loss due to hypogonadism, either identified during work-up of erectile dysfunction or induced by androgen deprivation therapy for treatment of prostate cancer. The availability of bisphosphonate drugs with proven efficacy in fracture reduction has revolutionized osteoporosis therapy in the past decade. The use of these agents has been traditionally based on data obtained predominantly from postmenopausal women and cases of glucocorticoid-induced osteoporosis, but data are becoming increasingly available to justify their use in men. Despite the availability and favorable safety profile of bisphosphonates, many patients are not receiving therapy. This article serves to review the data regarding bisphosphonate use in men, discussing particularly the pharmacology and mechanisms of action of these agents, and findings from clinical studies supporting their use for fracture prevention.

AB - Osteoporosis has long been recognized as a disease affecting postmenopausal women but it has become increasingly clear that men are affected by low bone density and suffer the consequences of osteoporotic fractures. Men attending clinical urological practices might be at raised risk of bone loss due to hypogonadism, either identified during work-up of erectile dysfunction or induced by androgen deprivation therapy for treatment of prostate cancer. The availability of bisphosphonate drugs with proven efficacy in fracture reduction has revolutionized osteoporosis therapy in the past decade. The use of these agents has been traditionally based on data obtained predominantly from postmenopausal women and cases of glucocorticoid-induced osteoporosis, but data are becoming increasingly available to justify their use in men. Despite the availability and favorable safety profile of bisphosphonates, many patients are not receiving therapy. This article serves to review the data regarding bisphosphonate use in men, discussing particularly the pharmacology and mechanisms of action of these agents, and findings from clinical studies supporting their use for fracture prevention.

UR - http://www.scopus.com/inward/record.url?scp=34250183139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250183139&partnerID=8YFLogxK

U2 - 10.1038/ncpuro0816

DO - 10.1038/ncpuro0816

M3 - Article

VL - 4

SP - 310

EP - 320

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 6

ER -